Medical Marijuana Pipeline Drugs Insights Report 2025 | DelveInsight

DelveInsight's, "Medical Marijuana Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 50+ pipeline drugs in Medical Marijuana pipeline landscape. It covers the Medical Marijuana pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Medical Marijuana pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Medical Marijuana Treatment Landscape @ Medical Marijuana Pipeline Outlook- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Medical Marijuana Pipeline Report
• On April, 2025, Syqe Medical revealed the initiation of a study designed to assess the effectiveness of medical cannabis aerosol containing 0.25, 0.5, and 1.0 milligrams (mg) of delta (Δ)9-tetrahydrocannabinol, administered three times daily (TID). The trial will compare this treatment to placebo using the Fixed-dose Syqe Inhaler, focusing on its impact on pain intensity at Week 15.
• DelveInsight's Medical Marijuana pipeline report depicts a robust space with 25+ active players working to develop 50+ pipeline therapies for Medical Marijuana treatment.
• The leading Medical Marijuana Companies such as Tetra Bio-Pharma, Corbus Pharmaceuticals, Bionorica SE, e3D Pharma, TO Pharmaceuticals, Therapix Biosciences, ANANDA Scientific, Daisy Pharma Opioid Venture, Canbex Therapeutics, InMed Pharmaceuticals, Botanix Pharmaceuticals, Centrexion Therapeutics, Tilray, One World Cannabis, Epm Group, Zelira Therapeutics, Pascal Biosciences, Cannovex, Can-Fite Pharma, GB Sciences, Serina Therapeutics, Oxford Technologies, Cannabis Science and others.
• Promising Medical Marijuana Pipeline Therapies such as NTI164, Medical Cannabis, MediCabilis Cannabis sativa 50, and others.

Discover groundbreaking developments in Medical Marijuana Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Medical Marijuana Clinical Trials Assessment- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Medical Marijuana Emerging Drugs Profile
• BX-1: Bionorica SE
BX-1 is an oral solution containing dronabinol, being developed by Bionorica. Dronabinol is a synthetic form of Δ9-, the primary psychoactive component of cannabis. The drug is currently in phase III stage of development for the treatment of spasticity in patients with multiple sclerosis not showing sufficient response to their current anti-spasticity treatment.

• Lenabasum: Corbus Pharmaceuticals
Corbus Pharmaceuticals is developing Lenabasum, and currently it is in phase III stage of development for the treatment of multiple indications, such as dermatomyositis, systemic scleroderma, cystic fibrosis, systemic lupus erythematosus etc. Lenabasum is a novel, oral, small molecule that selectively binds as an agonist to the cannabbinoid receptor type 2 (CB2) and resolves inflammation and limits fibrosis in animal and human models of disease. CB2 is preferentially expressed on activated immune cells and on fibroblasts, muscle cells, and endothelial cells.

• THX-110: Therapix Biosciences
THX-110 is a being developed by Therapix Biosciences. The drug candidate platform is for the treatment of symptoms related to Tourette syndrome (TS), as well as obstructive sleep apnea (OSA) and chronic pain. Therapix is seeking orphan drug designation for this compound. The THX-110 program takes a unique approach to cannabbinoid formulation using the Entourage Effect hypothesis (i.e., in which endocannabbinoid system constituents work synergistically together). THX-110 is a proprietary combination drug based on dronabinol and PEA. The drug is currently in phase II stage of development.

• Cannabis oil: TO Pharmaceuticals
TO Pharma is developing next-generation cannabbinoid therapies for debilitating diseases. TO pharmaceuticals is developing Cannabis oil, and currently, it is in phase II stage of development for the treatment of hidradenitis suppurativa and agitation related to dementia. The cannabis oil is made out of extract from the Avidekel strain and olive oil. Avidekel oil containing Δ9-Tetra-Hydrocannabinol (Δ9-) and in a 1:20 ratio and at a concentration of 30% and 1.5% Δ9-. Each Avidekel oil drop is approximately 0.04 mL in volume containing about 12 mg and 0.6 mg Δ9-. The oil is in the form of drops to be administered orally.

• VSN16R: Canbex Therapeutics
VSN16R is currently in phase II stage of development for the treatment of spasticity in people with multiple sclerosis. The orally active small molecule compound is being developed by Canbex Therapeutics, a spin-off of University College London (UCL). Preclinical and Phase I clinical studies have demonstrated that VSN16R has the potential to provide substantially better patient care than existing systemic anti-spastic treatments. VSN16R was shown to be safe and well-tolerated in its Phase I clinical safety trial. In the Phase I study, 72 healthy volunteers were enrolled in a placebo-controlled, single ascending- and multiple-ascending dose design.

• INM-755: InMed Pharmaceuticals
INM-755 is a cannabinol topical cream under development for the treatment of epidermolysis bullosa. INM-755 cream for EB is the first, and currently the only, cannabinol formulation being tested in clinical trials as a therapeutic product. The Phase 2 study, 755-201-EB, is designed to enroll up to 20 patients, conservatively within 10-12 months, and will take place at 10 pre-qualified clinical sites in several countries. All four subtypes of inherited EB, being EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome, are eligible for this study in which InMed will evaluate the safety of INM-755 (cannabinol) cream and its preliminary efficacy in treating symptoms and healing wounds over a 28-day period.

The Medical Marijuana Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Medical Marijuana with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Medical Marijuana Treatment.
• Medical Marijuana Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Medical Marijuana Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreements and financing details for future advancement of the Medical Marijuana market

Stay informed about the Medical Marijuana pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the industry @ Medical Marijuana Unmet Needs- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Medical Marijuana Companies
Tetra Bio-Pharma, Corbus Pharmaceuticals, Bionorica SE, e3D Pharma, TO Pharmaceuticals, Therapix Biosciences, ANANDA Scientific, Daisy Pharma Opioid Venture, Canbex Therapeutics, InMed Pharmaceuticals, Botanix Pharmaceuticals, Centrexion Therapeutics, Tilray, One World Cannabis, Epm Group, Zelira Therapeutics, Pascal Biosciences, Cannovex, Can-Fite Pharma, GB Sciences, Serina Therapeutics, Oxford Cannabbinoid Technologies, Cannabis Science and others.

Medical Marijuana pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Medical Marijuana Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Transform your understanding of the Medical Marijuana Pipeline! See the latest progress in drug development and clinical research @ Medical Marijuana Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Medical Marijuana Pipeline Report
• Coverage- Global
• Medical Marijuana Companies- Tetra Bio-Pharma, Corbus Pharmaceuticals, Bionorica SE, e3D Pharma, TO Pharmaceuticals, Therapix Biosciences, ANANDA Scientific, Daisy Pharma Opioid Venture, Canbex Therapeutics, InMed Pharmaceuticals, Botanix Pharmaceuticals, Centrexion Therapeutics, Tilray, One World Cannabis, Epm Group, Zelira Therapeutics, Pascal Biosciences, Cannovex, Can-Fite Pharma, GB Sciences, Serina Therapeutics, Oxford Cannabbinoid Technologies, Cannabis Science and others.
• Medical Marijuana Pipeline Therapies- NTI164, Medical Cannabis, MediCabilis Cannabis sativa 50, and others.
• Medical Marijuana Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Medical Marijuana Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Neurology Research-Access the Full Medical Marijuana Pipeline Analysis Today! @ Medical Marijuana Drugs and Companies- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Medical Marijuana: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. BX-1: Bionorica SE
8. Drug profiles in the detailed report.....
9. Mid Stage Products (Phase II)
10. THX-110: Therapix Biosciences
11. Drug profiles in the detailed report.....
12. Early stage products (Phase I/II)
13. CNTX 6016: Centrexion Therapeutics
14. Inactive Products
15. Medical Marijuana - Key Companies
16. Medical Marijuana - Key Products
17. Medical Marijuana - Unmet Needs
18. Medical Marijuana - Market Drivers and Barriers
19. Medical Marijuana - Future Perspectives and Conclusion
20. Medical Marijuana -Analyst Views
21. Medical Marijuana - Key Companies
22. Appendix

About Us

DelveInsight is a leading focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.